Poorly Controlled Type II Diabetes Mellitus Significantly Enhances Postoperative Chemoresistance in Patients with Stage III Colon Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Date 2025 Jan 22

PMID 39839894

Authors

Ruo-Yu Guan

Jia-Wei Wu

Zi-Yun Yuan

Zhi-Yuan Liu

Zi-Zhu Liu

Zhi-Cong Xiao

Jing-Hui Li

Cheng-Zhi Huang

Jun-Jiang Wang

Xue-Qing Yao

Affiliations

Soon will be listed here.

Abstract

Background: Type II diabetes mellitus (T2DM) has been associated with increased risk of colon cancer (CC) and worse prognosis in patients with metastases. The effects of T2DM on postoperative chemoresistance rate (CRR) and long-term disease-free survival (DFS) and overall survival (OS) in patients with stage III CC who receive curative resection remain controversial.

Aim: To investigate whether T2DM or glycemic control is associated with worse postoperative survival outcomes in stage III CC.

Methods: This retrospective cohort study included 278 patients aged 40-75 years who underwent surgery for stage III CC from 2018 to 2021. Based on preoperative T2DM history, the patients were categorized into non-DM ( = 160) and DM groups ( = 118). The latter was further divided into well-controlled ( = 73) and poorly controlled ( = 45) groups depending on the status of glycemic control. DFS, OS, and CRR were compared between the groups and Cox regression analysis was used to identify risk factors.

Results: Patients in the DM and non-DM groups demonstrated similar DFS, OS, and CRR (DFS: 72.03% 78.75%, = 0.178; OS: 81.36% 83.12%, = 0.638; CRR: 14.41% 7.5%, = 0.063). Poorly controlled DM was associated with a significantly worse prognosis and higher CRR than well-controlled DM (DFS: 62.22% 78.07%, = 0.021; OS: 71.11% 87.67%, = 0.011; CRR: 24.40% 8.22%, = 0.015). High preoperative fasting plasma glucose [DFS: Hazard ratio (HR) = 2.684, < 0.001; OS: HR = 2.105, = 0.019; CRR: HR = 2.214, = 0.005] and glycosylated hemoglobin levels (DFS: HR = 2.344, = 0.006; OS: HR = 2.119, = 0.021; CRR: HR = 2.449, = 0.009) indicated significantly poor prognosis and high CRR, while T2DM history did not (DFS: HR = 1.178, = 0.327; OS: HR = 0.933, = 0.739; CRR: HR = 0.997, = 0.581).

Conclusion: Increased preoperative fasting plasma glucose and glycosylated hemoglobin levels, but not T2DM history, were identified as risk factors associated with poor postoperative outcomes and high CRR in patients with stage III CC.

References

Uppada S, Gowrikumar S, Ahmad R, Kumar B, Szeglin B, Chen X . MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling. Mol Cancer. 2018; 17(1):111. PMC: 6090950. DOI: 10.1186/s12943-018-0848-3. View

Ruze R, Chen Y, Xu R, Song J, Yin X, Wang C . Obesity, diabetes mellitus, and pancreatic carcinogenesis: Correlations, prevention, and diagnostic implications. Biochim Biophys Acta Rev Cancer. 2022; 1878(1):188844. DOI: 10.1016/j.bbcan.2022.188844. View

Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021; 32(12):1496-1510. DOI: 10.1016/j.annonc.2021.08.1752. View

Gore M, McGuire D . A Test in Context: Hemoglobin A and Cardiovascular Disease. J Am Coll Cardiol. 2016; 68(22):2479-2486. DOI: 10.1016/j.jacc.2016.08.070. View

Zhang L, Zhao Y, Dai Y, Cheng J, Gong Z, Feng Y . Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol. 2018; 9:1578. PMC: 6048410. DOI: 10.3389/fimmu.2018.01578. View

Shin A, Giancotti F, Rustgi A . Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023; 44(4):222-236. PMC: 10365888. DOI: 10.1016/j.tips.2023.01.003. View

Tamas K, Walenkamp A, de Vries E, van Vugt M, Beets-Tan R, van Etten B . Rectal and colon cancer: Not just a different anatomic site. Cancer Treat Rev. 2015; 41(8):671-9. DOI: 10.1016/j.ctrv.2015.06.007. View

Cui Y, Liu H, Wang Z, Zhang H, Tian J, Wang Z . Fructose promotes angiogenesis by improving vascular endothelial cell function and upregulating VEGF expression in cancer cells. J Exp Clin Cancer Res. 2023; 42(1):184. PMC: 10375648. DOI: 10.1186/s13046-023-02765-3. View

Paschke S, Jafarov S, Staib L, Kreuser E, Maulbecker-Armstrong C, Roitman M . Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018; 19(9). PMC: 6165083. DOI: 10.3390/ijms19092577. View

10.

Miller K, Nogueira L, Devasia T, Mariotto A, Yabroff K, Jemal A . Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022; 72(5):409-436. DOI: 10.3322/caac.21731. View

11.

Selvin E, Steffes M, Zhu H, Matsushita K, Wagenknecht L, Pankow J . Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362(9):800-11. PMC: 2872990. DOI: 10.1056/NEJMoa0908359. View

12.

Tossetta G . Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. Int J Mol Sci. 2022; 23(21). PMC: 9654053. DOI: 10.3390/ijms232112893. View

13.

Oconnell M, Mailliard J, Kahn M, Macdonald J, Haller D, Mayer R . Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997; 15(1):246-50. DOI: 10.1200/JCO.1997.15.1.246. View

14.

Farrash W, Aslam A, Almaimani R, Minshawi F, Almasmoum H, Alsaegh A . Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells. Biofactors. 2023; 49(4):831-848. DOI: 10.1002/biof.1947. View

15.

Chen J, Yuan S, Fu T, Ruan X, Qiao J, Wang X . Gastrointestinal Consequences of Type 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study. Diabetes Care. 2023; 46(4):828-835. PMC: 10091506. DOI: 10.2337/dc22-1385. View

16.

Schmoll H, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015; 33(32):3733-40. DOI: 10.1200/JCO.2015.60.9107. View

17.

Li H, Li C, Zhang B, Jiang H . Lactoferrin suppresses the progression of colon cancer under hyperglycemia by targeting WTAP/mA/NT5DC3/HKDC1 axis. J Transl Med. 2023; 21(1):156. PMC: 9972781. DOI: 10.1186/s12967-023-03983-1. View

18.

. [Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]. Zhonghua Nei Ke Za Zhi. 2022; 61(1):12-50. DOI: 10.3760/cma.j.cn112138-20211027-00751. View

19.

Mao Y, Wang X, Xi L, Dong M, Song P, Miao J . Prediction values of tertiary lymphoid structures in the prognosis of patients with left- and right-sided colon cancer: a multicenter propensity score-matched study. Int J Surg. 2023; 109(8):2344-2358. PMC: 10442147. DOI: 10.1097/JS9.0000000000000483. View

20.

Adnan Almaimani R, Aslam A, Ahmad J, El-Readi M, El-Boshy M, Abdelghany A . In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network. Cancers (Basel). 2022; 14(6). PMC: 8946120. DOI: 10.3390/cancers14061538. View